那他利珠单抗在成年特应性皮炎治疗中的作用。
The role of nemolizumab in the treatment of atopic dermatitis for the adult population.
机构信息
Wake Forest School of Medicine, Dermatology Department, Winston-Salem, NC 27104, USA.
Rowan School of Osteopathic Medicine, Stratford, NJ 08084, USA.
出版信息
Immunotherapy. 2024;16(14-15):925-935. doi: 10.1080/1750743X.2024.2383554. Epub 2024 Aug 9.
Abstract
Atopic dermatitis (AD) often requires long-term treatment that may be associated with adverse effects. This review aims to characterize nemolizumab as a treatment for AD in adults. A literature search was performed to assess nemolizumab's role in moderate-to-severe AD in adults. Currently, clinical trials are being conducted to evaluate the clinical efficacy, safety profile and optimal dosing of nemolizumab for adults with moderate-to-severe AD. The most common adverse effects include nasopharyngitis, AD exacerbation and increased blood creatinine phosphokinase. Recent data from clinical trials suggest nemolizumab may be an acceptable treatment in adults with moderate-to-severe AD.
摘要
特应性皮炎（AD）常需长期治疗，且可能伴有不良反应。本综述旨在阐述度那利尤单抗在成人 AD 中的治疗作用。检索文献评估度那利尤单抗在成人中重度 AD 中的作用。目前正在开展临床试验以评估度那利尤单抗在成人中重度 AD 中的临床疗效、安全性特征和最佳剂量。最常见的不良反应包括鼻咽炎、AD 恶化和血肌酸磷酸激酶升高。来自临床试验的最新数据提示度那利尤单抗可能是成人中重度 AD 的一种可接受的治疗药物。
相似文献
1
The role of nemolizumab in the treatment of atopic dermatitis for the adult population.那他利珠单抗在成年特应性皮炎治疗中的作用。
Immunotherapy. 2024;16(14-15):925-935. doi: 10.1080/1750743X.2024.2383554. Epub 2024 Aug 9.
2
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
3
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.在一项开放性研究中，度普利尤单抗为中重度特应性皮炎成人患者提供了长达 4 年的可接受安全性和持续疗效。
Am J Clin Dermatol. 2022 May;23(3):393-408. doi: 10.1007/s40257-022-00685-0. Epub 2022 May 3.
4
Systemic treatments for eczema: a network meta-analysis.湿疹的全身治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD013206. doi: 10.1002/14651858.CD013206.pub2.
5
Educational and psychological interventions for managing atopic dermatitis (eczema).管理特应性皮炎（湿疹）的教育和心理干预措施。
Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014932. doi: 10.1002/14651858.CD014932.pub2.
6
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J).使用乐必妥单抗和外用糖皮质激素联合治疗中重度特应性皮炎的长期管理：在日本进行的一项为期68周的随机双盲安慰剂对照III期试验（ADhere-J）
Br J Dermatol. 2025 Mar 18;192(4):597-610. doi: 10.1093/bjd/ljae394.
7
Topical tacrolimus for atopic dermatitis.外用他克莫司治疗特应性皮炎。
Cochrane Database Syst Rev. 2015 Jul 1;2015(7):CD009864. doi: 10.1002/14651858.CD009864.pub2.
8
Conjunctivitis in Adults with Atopic Dermatitis Treated with Dupilumab: An Observational Study of Clinical Characteristics, Symptomatology, and Treatment.度普利尤单抗治疗成人特应性皮炎合并结膜炎：一项关于临床特征、症状学及治疗的观察性研究
Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03209-4.
9
Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis.专家视角：影响中重度特应性皮炎随机临床试验结果解读的关键参数
Am J Clin Dermatol. 2022 Jan;23(1):1-11. doi: 10.1007/s40257-021-00639-y. Epub 2021 Oct 26.
10
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.使用曲罗芦单抗治疗长达4年的头颈部特应性皮炎患者的长期疾病控制和最小疾病活动度
Am J Clin Dermatol. 2025 Mar 14. doi: 10.1007/s40257-025-00931-1.
引用本文的文献
1
Innovations and Emerging Therapies in Atopic Dermatitis Part 1.特应性皮炎的创新与新兴疗法 第1部分
Curr Treat Options Allergy. 2025;12. doi: 10.1007/s40521-025-00390-3. Epub 2025 May 7.
本文引用的文献
1
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus.真实世界临床实践中使用JAK抑制剂治疗中重度特应性皮炎患者：意大利德尔菲共识
Dermatol Ther (Heidelb). 2024 Apr;14(4):919-932. doi: 10.1007/s13555-024-01135-x. Epub 2024 Mar 21.
2
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.尼莫利珠单抗治疗结节性痒疹患者的 3 期临床试验。
N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333.
3
Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations.生物制剂与小分子药物治疗中重度特应性皮炎：临床考虑。
J Allergy Clin Immunol Pract. 2023 May;11(5):1361-1373. doi: 10.1016/j.jaip.2023.03.011. Epub 2023 Mar 21.
4
Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis.阻断白细胞介素-31通路作为特应性皮炎的潜在靶向治疗方法
Pharmaceutics. 2023 Feb 8;15(2):577. doi: 10.3390/pharmaceutics15020577.
5
Interleukin-31 Receptor A Expression in the Dorsal Root Ganglion of Mice with Atopic Dermatitis.特应性皮炎小鼠背根神经节中白细胞介素 31 受体 A 的表达。
Int J Mol Sci. 2023 Jan 5;24(2):1047. doi: 10.3390/ijms24021047.
6
European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy.欧洲特应性皮炎指南（EuroGuiDerm）：第一部分——系统治疗。
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1409-1431. doi: 10.1111/jdv.18345.
7
Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.尼莫利珠单抗：一种创新性的生物制剂，用于控制白细胞介素 31，这是特应性皮炎和结节性痒疹的关键介质。
Actas Dermosifiliogr. 2022 Jul-Aug;113(7):674-684. doi: 10.1016/j.ad.2021.12.014. Epub 2021 Dec 23.
8
Nemolizumab: First Approval.尼莫珠单抗：首次批准。
Drugs. 2022 Jul;82(10):1143-1150. doi: 10.1007/s40265-022-01741-z. Epub 2022 Jul 14.
9
Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.Nemolizumab 治疗瘙痒性特应性皮炎的安全性和疗效：一项随机对照试验的系统评价和荟萃回归分析。
Front Immunol. 2022 Apr 26;13:825312. doi: 10.3389/fimmu.2022.825312. eCollection 2022.
10
Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk.瘙痒：一种在皮肤免疫-神经相互作用中产生的感觉症状。
Front Pharmacol. 2022 Mar 7;13:745658. doi: 10.3389/fphar.2022.745658. eCollection 2022.
Zotero 插件